Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Pharmacotherapies for diabetic retinopathy: present and future Schwartz SG; Flynn HW JrExp Diabetes Res 2007[]; 2007 (ä): 52487Diabetic retinopathy remains a major cause of worldwide preventable blindness. Measures to avoid blindness include medical management (control of blood sugar, blood pressure, and serum lipids) and ocular management (laser photocoagulation and pars plana vitrectomy). Adjunctive pharmacologic therapies (intravitreal triamcinolone acetonide and anti-vascular endothelial growth factor agents) have shown early promise in the treatment of both diabetic macular edema and proliferative diabetic retinopathy. Other medications under investigation include the fluocinolone acetonide implantable device, extended-release dexamethasone implant, oral ruboxistaurin, and intravitreal hyaluronidase.|Adrenal Cortex Hormones/therapeutic use[MESH]|Diabetic Retinopathy/*drug therapy[MESH]|Enzyme Inhibitors/therapeutic use[MESH]|Humans[MESH]|Hyaluronoglucosaminidase/therapeutic use[MESH]|Indoles/therapeutic use[MESH]|Maleimides/therapeutic use[MESH]|Ophthalmology/trends[MESH]|Practice Guidelines as Topic[MESH]|Vascular Endothelial Growth Factor A/antagonists & inhibitors[MESH] |